Compare 3M Company (MMM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Natera Inc. Common Stock — how do they compare? 3M Company trades at $164.93 (market cap $83.94B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: 3M Company is the larger of the two by market cap, and 3M Company pays a 1.92% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Natera Inc. Common Stock for 0 Days on average.
| MMM | NTRA | |
|---|---|---|
Market Cap | $83.94B | $57.03B |
Volume | 2,547,210 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $183.79 | $425.64 |
52-Week Low | $141.10 | $179.42 |
Typical Hold Time | 169 Days | 0 Days |
Enterprise Value | $93.17B | $56.18B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $164.46, up 2.22% with strong recent earnings beats and a bullish analyst consensus price target of $191. The stock shows bearish technical signals but maintains solid fundamentals with 11.9% net margins and 82.77% ROE. Recent Q2 2026 results confirmed operational improvements with 5.4% organic growth and raised guidance, though technical indicators suggest near-term pressure.
The outlook remains positive with manageable litigation risks and strategic focus on high-growth areas like data centers. Key risks include consumer segment weakness and debt levels. Wall Street sentiment is balanced with 48% buy ratings, supporting potential upside from current levels despite technical bearishness.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
